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Anemia is a new complication in Fabry disease: Data from the
Fabry Outcome Survey.
Background. The prevalence and causes of anemia among
patients with Fabry disease are unknown.
Methods. In a cross-sectional study we examined hemoglobin
concentrations of patients with Fabry disease using a large in-
ternational database, the Fabry Outcome Survey (FOS), and
analyzed the association of renal function, heart failure,
gastrointestinal symptoms, and inflammation, with anemia
(hemoglobin <12 g/dL in females and <13 g/dL in males).
Results. Anemia was present in 34% of 345 patients with
Fabry disease. Median hemoglobin in 158 females was 12.9 g/dL
and the median hemoglobin of 187 male patients was 13.2 g/dL.
The prevalence of anemia among females was 20%, and among
males 47%. Among patients with normal renal function [esti-
mated glomerular filtration rate (GFR) >90 mL/min/1.73 m2]
and anemia, heart failure [New York Heart Association
(NYHA) class II to IV] and/or elevated C-reactive protein
(CRP) levels were documented in 82% of patients. Up to 67%
of patients with decreased estimated GFR presented with ane-
mia. There was also a trend for lower hemoglobin levels among
patients with signs of inflammation (defined by an elevated CRP
level). We observed no association of the presence of gastroin-
testinal symptoms with anemia. Analyses in 53 patients receiv-
ing enzyme replacement therapy for up to 2 years, suggest no
effect on anemia.
Conclusion. The results of this study point to a high preva-
lence of anemia among patients with Fabry disease that is in
most instances related to impaired renal function, heart failure,
and inflammation. This finding may be of clinical relevance, be-
cause anemia is a major risk factor for patients with kidney
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disease, heart failure, or stroke, which are important manifes-
tations of Fabry disease.
Fabry disease is a rare X-linked lysosomal storage
disease [1]. Deficient activity of ∝-galactosidase A [2]
results in accumulation of glycosphingolipids, predom-
inantly globotriaosylceramide, within the lysosomes of
multiple tissues and organs [3] and may lead to end-stage
renal disease (ESRD), left ventricular hypertrophy, ar-
rhythmia, cerebrovascular disease and, ultimately to pre-
mature death. In contrast to many other diseases with
X-linked inheritance, many of the heterozygotes are also
affected [4, 5]. Fabry disease is a multisystem disorder pre-
senting with impairment of renal function, heart failure,
and gastrointestinal disturbances as potential causes for
different types of anemia, including renal anemia, ane-
mia of heart failure, or anemia of nutritional deficiencies.
Therefore, anemia might be a frequent and important
complication of Fabry disease. Furthermore, Fabry dis-
ease may also be associated with anemia of chronic dis-
ease or inflammation, as reflected by elevated C-reactive
protein (CRP) levels. Because anemia is a risk factor for
morbidity and mortality among patients with renal [6],
cardiac [7–9], or cerebrovascular disease [10], it may be
of clinical importance in the majority of patients with
Fabry disease. However, data on anemia in Fabry dis-
ease are scarce [11] and the prevalence of anemia in this
particular patient population is unknown. We therefore
analyzed hemoglobin concentration and the prevalence
of anemia in patients with Fabry disease enrolled in a
large international database, the Fabry Outcome Survey
(FOS) [12].
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METHODS
Design
Hemoglobin concentrations and the prevalence of
anemia among all patients with Fabry disease in FOS
were examined in a cross-sectional study. In a subset of
these patients, we examined anemia during enzyme re-
placement therapy with agalsidase alfa for at last 2 years.
FOS
The FOS data base has been approved by the institu-
tional ethical review boards of participating centers, and
all patients gave written informed consent. At the time of
this analysis (March 2004), FOS contained data on 545 pa-
tients (281 males and 264 females) with Fabry disease.
On enrollment in FOS, each patient’s medical history
is documented, including the year of diagnosis of Fabry
disease, signs and symptoms of the disease (cerebrovas-
cular, neurologic, psychiatric, ear, eye, cardiac, blood
pressure, vascular, respiratory, renal, gastrointestinal,
genital, musculosceletal, dermatologic, endocrinologic,
and general symptoms), treatment, demographic details,
and family history. All measurements performed rou-
tinely in clinical practice (e. g., serum creatinine, pro-
teinuria, hemoglobin, CRP), including follow-up data
during enzyme replacement therapy, can be entered in
the data base [13]. Laboratory data on iron status, folate
levels, and vitamin B12 levels are not routinely requested
in the data base. Data on current therapy with iron and
erythropoiesis-stimulating agents were also included in
this analysis. Anonymous data are submitted electroni-
cally by participating physicians to the central FOS data
base.
A priori definitions
Corresponding to the definition of the world health or-
ganization (http://www.who.int/nut/documents/ida assess
ment prevention control.pdf ), we defined anemia in
adults as a hemoglobin level of less than 12 g/dL in fe-
males and of less than 13 g/dL in males [14]. Glomerular
filtration rate (GFR) was estimated using the short Mod-
ification of Diet in Renal Disease (MDRD) formula for
assessment of renal function [15]. Renal function was
classified according to National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative (K/DOQI)
guidelines [16]. The definition of chronic kidney dis-
ease was as follows: stage 1, estimated GFR >90
mL/min/1.73 m2 (we also included patients with no signs
of kidney damage, such as proteinuria or hematuria, in
this patient group); stage 2, 60 to 89 mL/min/1.73 m2; stage
3, 30 to 59 mL/min/1.73 m2; stage 4, 15 to 29 mL/min/1.73
m2; and stage 5, <15 mL/min/1.73 m2 or dialysis. Heart
failure [without classifying it according to the New York
Heart Association (NYHA)] and presence of gastroin-
testinal symptoms was defined by participating investiga-
tors as being present or absent.
Statistical analysis
Numbers are shown as medians (10th percentile and
90th percentile). Statistical analyses were performed us-
ing Spearman’s correlation coefficient for ranked data,
the chi-square test, Wilcoxon’s rank sum test, and the
Kruskal-Wallis one-way analysis of variance (ANOVA).
Linear associations were assessed by Pearson correlation.
In cross-sectional follow-up of hemoglobin concentra-
tions, minimum values for individual patients were used.
Longitudinal follow-up of hemoglobin at baseline, 1 year,
and 2 years was performed using individual patient’s min-
imum values reported at –6 to +3 months around the
start of enzyme replacement therapy for baseline, 9 to
15 months after the start of enzyme replacement therapy,
and 21 to 27 months after the start of enzyme replacement
therapy, respectively.
Role of the funding source
Data collection and analysis in FOS are supported by
TKT Europe – 5S (Danderyd, Sweden). The sponsor had
no role in the design of the study, the interpretation of
data, or writing of the manuscript.
RESULTS
Patients
Among 545 patients with Fabry disease registered in
FOS as of March 2004, 345 adults (including patients on
dialysis and those with kidney transplants; age >18 years)
had hemoglobin measurements entered in the data base.
The characteristics of the patients are given in Table 1.
Patients in this analysis were recruited from 11
European countries (Germany, 23%; Czech Republic,
11%; United Kingdom, 14%; Switzerland, 10%; Italy,
9%; Belgium, 6%; Spain, 8%; Sweden, 4%; Austria, 3%;
France, 7%; and Norway, 5%).
Hemoglobin concentration and prevalence of anemia
The prevalence of anemia among females was 20% (31)
and among males 47% (87) (P < 0.05). There was no lin-
ear association between hemoglobin concentrations and
age in either female or male patients. However, we ob-
served a negative correlation between hemoglobin con-
centration and the number of organ systems affected by
Fabry disease in male patients (N = 186) (P = 0.006) but
not in females (N = 144).
Erythropoietin or iron therapy was reported in ten
patients. Two female patients received oral iron supple-
ments. Six male patients were on erythropoietin therapy,
and another two male patients received oral iron therapy.
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Table 1. Characteristics of the 345 patients with Fabry disease in the Fabry Outcome Survey from whom hemoglobin concentrations are available
All patients Females Males
Median Median Median
Number (10th and 90th percentile) Number (10th and 90th percentile) Number (10th and 90th percentile)
Age at entry years 345 40.1 (23.9 and 58.6) 158 44.5 (25.1 and 64.0) 187 36.3 (23.5 and 53.8)
Age at diagnosis years 320 31.5 (13.0 and 51.0) 140 39 (17.0 and 54.0) 180 26.0 (11.0 and 46.5)
Hemoglobin g/dL 345 13.5 (11.1 and 14.9) 158 12.9 (11.3 and 14.1) 187 13.2 (10.9 and 14.8)
Serum creatinine mg/dL 343 1.0 (0.8 and 1.7) 157 0.9 (0.7 and 1.1) 186 1.1 (0.8 and 2.7)
Serum C-reactive protein mg/L 160 2.7 (1.0 and 10.6) 80 2.3 (0.9 and 9.1) 80 2.9 (1.0 and 14.6)
Table 2. Median hemoglobin and proportion of 343 adult patients
with Fabry disease with anemia according to estimated glomerular
filtration rate class and renal replacement therapy modality
Prevalence of anemia
Estimated Median hemoglobin g/dL
GFR (10th and 90th percentile) Males Females
>90 13.3 (11.3 and 14.8) 37% (26/71) 26% (7/27)
60–89 13.1 (11.8 and 14.4) 37% (22/60) 17% (16/95)
<60 12.7 (10.6 and 14.2) 67% (20/30) 23% (8/35)
Dialysis 10.7 (8.9 and 12.8) 100% (9/9) –
Transplant 12.0 (10.2 and 14.6) 63% (10/16) –
Hemoglobin and renal function
Both hemoglobin concentrations and GFR estimates
were available in 318 adult patients (excluding those who
were receiving dialysis or had had a kidney transplant)
(Table 2). Three of the dialysis patients were reported to
receive erythropoiesis-stimulating agents, four did not re-
ceive erythropoiesis-stimulating agents, and concomitant
medication was not reported in two patients. The median
estimated GFR in patients with a kidney graft (N = 16)
was 43 (11 and 90) mL/min/1.73 m2. The proportion of
patients presenting with anemia, according to estimated
GFR class, is shown in Table 2. A hemoglobin concentra-
tion of less than 11 g/dL, the threshold for treatment with
erythropoiesis-stimulating agents, was observed in 118 of
345 patients (34%).
Among patients with an estimated GFR of less than 60
mL/min/1.73 m2 anemia was more prevalent as compared
to patients with an estimated GFR of ≥60 mL/min/1.73
m2 [all patients 61% versus 30% (P < 0.001); females
35% versus 19% (P = 0.13); and males 69% versus 40%
(P = 0.0005)].
By univariate analysis we found no linear associa-
tion between proteinuria and hemoglobin concentrations
(r = −0.037, P = 0.574).
Hemoglobin and heart failure
Among 98 patients with an estimated GFR greater than
90 mL/min/1.73 m2, median hemoglobin concentration
did not differ between the patients (N = 54) with heart
failure (13.2 (11.3 and 14.6) g/dL) and without [13.6 (11.8
and 14.9) g/dL] (P = 0.27). Of the 33 patients with an esti-
mated GFR greater than 90 mL/min/1.73 m2 and anemia,
19 (58%) had heart failure.
Hemoglobin and gastrointestinal symptoms
The presence or absence of gastrointestinal symptoms
was documented in 332 patients. In females, 58% (85 of
146 patients), and in males 62% (115 of 186 patients)
were reported to present with gastrointestinal symptoms
related to Fabry disease (NS). Among patients with ane-
mia, 67% (77 of 115 patients), and among patients with-
out anemia 57% (123 of 217 patients) presented with
gastrointestinal symptoms (NS).
Hemoglobin and inflammation
The level of CRP was reported in 169 patients, 56 (33%)
had elevated CRP levels. The median hemoglobin con-
centration was 13.1 (11.3 and 14.5) g/dL in patients with
normal CRP levels and 12.8 (10.6 and 14.2) g/dL (P =
0.07) in patients with elevated CRP levels. There was no
difference in hemoglobin levels in female and male pa-
tients with normal versus elevated CRP levels (P = 0.14).
Hemoglobin, GFR estimates, and CRP levels were re-
ported in 155 patients; 18 out of 49 patients (37%) with
elevated CRP levels, and 25 out of 106 patients (24%)
with normal CRP levels, had anemia (P = 0.089).
Elevated CRP levels were reported in 33% (36/108)
of patients with a decreased estimated GFR and in 28%
(13/47) of patients with a normal estimated GFR. The me-
dian hemoglobin concentrations in patients with an esti-
mated GFR greater than 90 mL/min/1.73 m2 with normal
(N = 34) versus elevated CRP (N = 13) were 13.4 (12.3
and 14.8) g/dL and 13.0 (11.3 and 14.6) g/dL, respectively.
Out of the 33 anemic patients with an estimated GFR
greater than 90 mL/min/1.73 m2 CRP levels were avail-
able in 17. Of these, five patients had heart failure and an
elevated CRP level, nine patients had heart failure and a
normal CRP level, and three patients had a normal CRP
level and no heart failure. Thus, in 82% of patients with an
estimated GFR greater than 90 mL/min/1.73 m2, anemia
may be related to heart failure, inflammation or both.
Hemoglobin concentrations during enzyme
replacement therapy
During enzyme replacement therapy with agalsi-
dase alfa (ReplagalTM) (TKT Europe) (0.2 mg/kg body
weight every 2 weeks intravenously) [17] in 53 pa-
tients (15 females and 38 males) the median hemoglobin
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concentration was 13.5 (11.8 and 14.7) g/dL at baseline,
13.3 (11.7 and 15.0) g/dL after 12 months, and 13.5 (12.2
and 14.6) g/dL after 24 months (P = 0.9). The prevalence
of anemia was 26% at baseline, 30% at 1 year, and 23%
at 2 years of enzyme replacement therapy.
DISCUSSION
This study provides evidence for a high prevalence of
anemia among adult patients with Fabry disease. Major
causes of anemia are impaired renal function, heart fail-
ure, and inflammation. Among patients with an estimated
GFR of less than 60 mL/min/1.73 m2, up to 69% presented
with anemia. Of note, up to 40% of patients with an es-
timated GFR ≥60 mL/min/1.73 m2 were also anemic. Of
the anemic patients with a GFR estimated to be normal,
82% presented with heart failure and/or inflammation.
The major cause of anemia in patients with renal dis-
ease is erythropoietin deficiency and insufficiency of iron
[18]. In chronic kidney disease, hemoglobin levels decline
in parallel with the decrease in GFR [19], finally resulting
in severe anemia in about 95% of individuals with ESRD
and dialysis treatment. Considering a cut point of GFR of
60 mL/min/1.73 m2 that has been previously suggested to
distinguish moderate chronic kidney disease (GFR <60
mL/min/1.73 m2) from better renal function (GFR ≥60
mL/min/1.73 m2) [16], anemia was reported in 61% and
30% of our patients, respectively. These numbers are in
stark contrast to results of a large study of 13,716 partic-
ipants in the prospective Atherosclerosis Risk In Com-
munities (ARIC) Study, where anemia was reported in
12.2% of individuals with an estimated GFR of <60
mL/min/1.73 m2 and in 8.7% of individuals with an esti-
mated GFR ≥60 mL/min/1.73 m2 [10]. Thus, the present
study suggests that anemia is more prevalent in either
Fabry patients with advanced chronic kidney disease or
in Fabry patients with better renal function as compared
to a community-based population.
Given this excess prevalence of anemia in our large
population of patients with Fabry disease, potential other
causes of anemia, such as heart failure or inflamma-
tion, deserve consideration. In patients with heart fail-
ure, anemia, related to an increased abundance of sev-
eral cytokines that impair erythropoiesis, may be of con-
siderable importance [20]. In this context, several large
studies have demonstrated a high prevalence of anemia
among patients with heart disease [20]. Recently, a new
concept has been developed that relates heart failure,
kidney failure, and anemia in a vicious circle, where each
of the three symptoms has a negative effect on the other
two [21]. This vicious circle has been described as the
cardio-renal-anemia syndrome, and is applicable to Fabry
disease, where heart failure and kidney disease play a
prominent role.
Systemic disorders such as Fabry disease may also
result in the hypoproliferative anemia of chronic dis-
ease, which is commonly normochromic or mildly
hypochromic anemia. The major cause of the anemia of
chronic disease is a disturbance of erythropoiesis due to
reduced production of, and sensitivity to, erythropoietin
[22]. Inflammation, as reflected by elevated CRP lev-
els, may also be related to infection and can adversely
affect hemopoiesis by many mechanisms in addition to
nonspecific suppression of erythropoietin production and
erythropoiesis through the production of inflammatory
mediators [23]. A characteristic of the anemia of chronic
disease is an abnormality of iron distribution as reflected
by low levels of iron in serum and decreased transferrin
saturation despite adequate storage, but with a reduction
of iron granules in marrow erythroblasts [22–24].
Among the patients with Fabry disease in the present
study, a high proportion of anemic individuals with a nor-
mal estimated GFR showed heart failure and/or inflam-
mation, pointing to a significant role of the anemia of
chronic disease in this specific patient group. Although
the cause of heart disease in Fabry disease is well es-
tablished, the reason for the high prevalence of elevated
levels of CRP among patients with Fabry disease is cur-
rently unknown. Remarkably, the proportion of patients
with elevated CRP levels was high among individuals with
a decreased estimated GFR and also in patients with a
normal estimated GFR. Therefore, inflammation may be
an additional contributor to anemia not only in patients
with impaired renal function. Notably, we also observed
a negative correlation between hemoglobin concentra-
tion and the number of organ systems involved in male
patients, but not in females. This finding may be related
to the more severe presentation of disease among male
patients and may point to a substantial role in the anemia
of chronic disease in Fabry disease. Thus, the high fre-
quency of renal failure, heart failure, and inflammation
in patients with Fabry disease makes this population so
unique for developing anemia.
Gastrointestinal symptoms are frequently reported in
patients with Fabry disease and represent a potential
cause for micronutrient malnutrition resulting in anemia
of iron, folate, or vitamin B12 deficiency. In our patient
population, however, the proportion of patients with gas-
trointestinal symptoms did not differ between anemic and
no anemic individuals.
In the general population, anemia is an important risk
factor for heart failure, myocardial infarction, and stroke
[7–10]. Therefore, the present study paves the way for
future analyses that should examine the effect of anemia
and its correction on morbidity and mortality in patients
with Fabry disease. These patients show an excess mor-
tality compared with the general population, with death
occurring on average at 50 years of age in males [11]. Life
expectancy is also significantly impaired in females [4].
Enzyme replacement therapy for Fabry disease was in-
troduced into clinical practice several years ago [17, 25]
and may improve the morbidity and premature mortality
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associated with the disease. In our analysis, hemoglobin
levels and the prevalence of anemia did not change dur-
ing a 2-year period of enzyme replacement therapy that
may be related to the stabilization of kidney function or
heart disease during enzyme replacement therapy.
The limitations of the present study are the lack of re-
porting iron status or folate and vitamin B12 levels in the
FOS data base. Information on therapy with erythropoi-
etic agents, iron or vitamins is not specifically requested
to be entered in the database and is therefore proba-
bly not complete. Thus, we cannot exclude a major role
of micronutrient deficiency on anemia in this cohort of
patients with Fabry disease. Importantly, iron deficiency
that may contribute to anemia in a substantial propor-
tion of our patients was not considered in our analysis. We
have not performed bone marrow analyses in our patients
and we are not aware of any other study examining the
morphology of the bone marrow in patients with Fabry
disease. Therefore, we cannot reject bone marrow accu-
mulation of Gb3 as potential cause of anemia in our study
population. Furthermore, assessment of renal function
using the MDRD GFR formula has not been formally
examined in patients with Fabry disease. In addition, the
methods used for measurement of serum creatinine in
the different centers participating in FOS vary due to
lack of international standardization of creatinine deter-
mination in clinical laboratories [26, 27]. Therefore, the
stage of chronic kidney disease, as estimated according to
the K/DOQI guidelines, may be missclassified in some of
the patients.
CONCLUSION
The results of this study point to an excess prevalence
of anemia in patients with Fabry disease. This finding may
be of considerable importance, as anemia is a risk factor
for patients with kidney disease, heart failure or stroke,
which are important manifestations of Fabry disease. Fur-
thermore, we have demonstrated the potential of a large
international database for identifying a hitherto unknown
and underrecognized complication of a rare monogenic
disease.
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